GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
about
Use of a German longitudinal prescription database (LRx) in pharmacoepidemiologyDo patients with lactose intolerance exhibit more frequent comorbidities than patients without lactose intolerance? An analysis of routine data from German medical practices.Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation modelChallenges in implementing and maintaining osteoporosis therapy.Alendronate soluble solution: a higher adherence rate in the treatment of osteoporosis.Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.The over time development of chronic illness self-management patterns: a longitudinal qualitative study.Clinical utility of denosumab for treatment of bone loss in men and womenEarly (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.Long-term persistence with anti-osteoporosis drugs after fracture.Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulationPersistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional studyPersistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysisCompliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.Drug holidays: the most frequent type of noncompliance with calcium plus vitamin D supplementation in persistent patients with osteoporosis.Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosisBisphosphonates adherence for treatment of osteoporosis.Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?Which Bisphosphonate? It's the Compliance!: Decision Analysis.Association between gastrointestinal events and compliance with osteoporosis therapy.GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.Gender- and age-related treatment compliance in patients with osteoporosis in Germany.Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United StatesVery high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study.Management of cancer treatment-induced bone loss.Bisphosphonate use and subsequent hip fracture in South Korea.Denosumab: a review of its use in postmenopausal women with osteoporosis.One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost.Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary.Comorbidities, bone-sparing agent prescription history and their determinants among postmenopausal women in UK primary care settings: a retrospective database study.Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.Persistency with estrogen replacement therapy among hysterectomized women after the Women's Health Initiative study.3-D bone models to improve treatment initiation among patients with osteoporosis: A randomised controlled pilot trial.Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era.
P2860
Q26785420-9DB2B970-A217-4AA6-8D6E-926EE52DA70CQ31073460-2C276619-1548-49A7-B831-0E1041D0338BQ33841204-A1A59694-9A57-4B8D-8772-32A2942393D3Q33986422-F004113E-2289-4ADF-B80B-36252C1DDE68Q34073740-DA458FD1-9133-4BCB-AF8B-095E801BC6FCQ34230314-09CE87CF-1CF7-4FFD-951F-CE71620EFF78Q34459547-F26C9B46-5B91-427A-8E48-89CF921519D1Q34707566-6ED8415F-47C1-4826-994D-0812B30D34CFQ35092799-5E871BC5-25E7-4D0E-9D23-3972A2F68828Q35707347-737F4AE8-B1DC-41C0-B055-32DABC6E9CF9Q35747751-D40DA264-E308-4319-B1E7-F728B3A43ADCQ35905973-B9BD48C8-D7E5-45EB-8370-9708F7DFE9DFQ36073613-BB57C857-2A6F-41E3-954F-F8A403F08CC3Q36073645-E435DD32-F53A-44A5-AC2F-A416D23B423BQ36343783-65C9005C-E5F1-405E-A682-878C31EB97B5Q36356633-7F27C716-E737-4A57-AF61-750A840C51D1Q36399034-82E79D00-CCC6-4B25-B9C3-A04AA639DDDBQ36795687-235AE68A-7AC5-48C9-8095-55217970D956Q36908527-EDF17CBE-2A22-4989-AC09-26C024C4B864Q36989616-4FD21C87-E58F-4F22-BEE9-730A9E8D724DQ36989633-EFB57208-5F10-49CC-827D-79F1FC19E63CQ37051660-9E286C7C-538B-4A60-8FFC-0EBB5A91DDEAQ37298020-AA3C2823-235F-44EB-AE8B-872FEB409794Q37446418-28492349-D9CF-4863-AAB9-D0731E6C12F8Q37670574-9A66FDCE-932C-4083-86E8-8C71DB4860DBQ37720586-975C65C5-4744-483C-A835-3BB3296D290DQ38090917-F702A660-EDC5-45E2-A89E-656F548027B4Q38107388-88330156-D130-4E4E-8132-29C4C4FA2232Q38220743-63096259-D454-4186-B819-61F1E7BA98A6Q38676331-C953D2F4-2C0D-4043-9FF4-4522292BC7D7Q38788967-D8D1F231-956B-4E84-8660-5CFABB7077EDQ38918810-D776791D-DA32-4C0D-A743-F71102506536Q39204185-79D19579-FF12-4422-959A-B15D6ACE8BC9Q40189823-7DC055D6-2001-45E1-9A59-B1B8F71351C1Q40300226-B2EDA8B0-C319-401D-A48C-4CE1D1C77211Q40372812-266F720D-EF63-484A-B911-37CD18966952Q40375149-77C4CF74-2108-4D09-9894-292814D64DB9Q40379928-6CF66DB8-826D-4B49-8D14-4F1B2C8FD8AEQ40688871-B2772603-D55B-4F8D-9EA2-5B23DB7AF467Q41111878-E77286B1-ADD0-483F-B29B-AE4D5AECB70F
P2860
GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
GRAND: the German retrospectiv ...... ted with oral bisphosphonates.
@en
GRAND: the German retrospectiv ...... ted with oral bisphosphonates.
@nl
type
label
GRAND: the German retrospectiv ...... ted with oral bisphosphonates.
@en
GRAND: the German retrospectiv ...... ted with oral bisphosphonates.
@nl
prefLabel
GRAND: the German retrospectiv ...... ted with oral bisphosphonates.
@en
GRAND: the German retrospectiv ...... ted with oral bisphosphonates.
@nl
P2093
P2860
P1476
GRAND: the German retrospectiv ...... ted with oral bisphosphonates.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-011-1535-Z
P407
P577
2011-02-10T00:00:00Z